# Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

> **NCT03274375** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 20 (estimated)

## Conditions studied

- Anti-NMDAR Encephalitis

## Interventions

- **DRUG:** IA session
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03274375
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-23
- **Primary completion:** 2024-07
- **Final completion:** 2026-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03274375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03274375, "Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03274375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*